Pharmacist-Led Medication Counseling and Its Effect on Treatment Adherence in Patients with Chronic Diseases

Authors

  • Naif Awad D Alrwaili
  • Budur Siyar Almutrafi
  • Mohammad Mansour N Alreshdi
  • Abdulrahman Jelwi S Alenazi
  • Jeza Saleh Alzabni
  • Aljubayri, Hezam Hathal H
  • Abdulrahman Olayan Alruwaili
  • Ali Holel N Alenezi
  • Saud Ibrahim Hassan Aldakhil
  • Khaled Mohammad Naseer Al Suhali
  • Mufreh Ames Mlahad Alrowily

DOI:

https://doi.org/10.22399/ijcesen.4673

Keywords:

Pharmacist-led counseling, Medication Adherence, treatment compliance, chronic disease management, pharmaceutical care

Abstract

Pharmacist-led medication counseling represents a critical intervention in chronic disease management, directly addressing the pervasive challenge of medication non-adherence. By transitioning from a dispensing role to a patient-centered practice, pharmacists conduct structured, tailored consultations that assess individual barriers, educate on proper medication use, and employ behavioral strategies to empower patients. This evidence-based approach, grounded in theories like the Health Belief Model and Motivational Interviewing, systematically improves treatment adherence across conditions such as hypertension, diabetes, and asthma. Enhanced adherence subsequently leads to superior clinical outcomes, reduced complications, and more efficient healthcare utilization. Ultimately, integrating pharmacists as proactive counselors within the care team is essential for optimizing long-term therapeutic success and public health in the era of chronic diseases.

References

[1] Levin A, Stevens PE, Bilous RW, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.

[2] Luyckx VA, Tuttle KR, Garcia-Garcia G, et al. Reducing major risk factors for chronic kidney disease. Kidney Int. 2017;7(2):71–87.

[3] Tesfaye WH, McKercher C, Peterson GM, et al. Medication adherence, burden and health-related quality of life in adults with predialysis chronic kidney disease: a prospective cohort study. Int J Environ Res Public Health. 2020;17(1):371.

[4] Parvez MK, Rishi V. Herb-drug interactions and hepatotoxicity. Curr Drug Metab. 2019;20(4):275–282.

[5] Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662–664.

[6] Anderson LJ, Nuckols TK, Coles C, et al. A systematic overview of systematic reviews evaluating medication adherence interventions. Am J Health Syst Pharm. 2020;77(2):138–147.

[7] Ljung R, Lu Y, Lagergren J. High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study. Drugs Aging. 2011;28(6):469–476.

[8] Kimura H, Tanaka K, Saito H, et al. Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol. 2021;16(12):1797–1804.

[9] Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11.

[10] Tangkiatkumjai M, Walker DM, Praditpornsilpa K, Boardman H. Association between medication adherence and clinical outcomes in patients with chronic kidney disease: a prospective cohort study. Clin Exp Nephrol. 2017;21(3):504–512.

[11] Rashid R, Chang C, Niu F, et al. Evaluation of a pharmacist-managed nonsteroidal anti-inflammatory drugs deprescribing program in an integrated health care system. J Manag Care Spec Pharm. 2020;26(7):918–924.

[12] Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256.

[13] Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118–123.

[14] Hayward S, Hole B, Denholm R, et al. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study. Nephrol Dial Transplant. 2021;36(3):503–511.

[15] van Berlo-van de Laar IRF, Sluiter HE, Riet EV, Taxis K, Jansman FGA. Pharmacist-led medication reviews in pre-dialysis and dialysis patients. Res Social Adm Pharm. 2020;16(12):1718–1723.

[16] Schmidt IM, Hubner S, Nadal J, et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German chronic kidney disease study. Clin Kidney J. 2019;12(5):663–672.

[17] Shivaprasad S, Mateti UV, Shenoy P, Shastry CS, Dharmagadda S. Clinical pharmacists’ scope of knowledge for medication therapy management in chronic kidney disease patients. Pharm Educ. 2021;21(1):781–788.

[18] Pai AB. Keeping kidneys safe: the pharmacist’s role in NSAID avoidance in high-risk patients. J Am Pharm Assoc. 2015;55(1):e15–23; quiz e24–5.

[19] Griffin BR, Wendt L, Vaughan-Sarrazin M, et al. Nephrotoxin exposure and acute kidney injury in adults. Clin J Am Soc Nephrol. 2023;18(2):163–172.

[20] Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. Clinical pharmacy practice in the care of chronic kidney disease patients: a systematic review. Int J Clin Pharm. 2019;41(3):630–666.

[21] de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–3090.

[22] United States Renal Data System. USRDS annual data report: epidemiology of kidney disease in the United States; 2022. Available from: https://adr.usrds.org/2022. Accessed August 6, 2023.

[23] Cedillo-Couvert EA, Ricardo AC, Chen J, et al. Self-reported medication adherence and CKD progression. Kidney Int Rep. 2018;3(3):645–651.

[24] Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014;70(10):1159–1172.

[25] Roumeliotis N, Sniderman J, Adams-Webber T, et al. Effect of electronic prescribing strategies on medication error and harm in hospital: a systematic review and meta-analysis. J Gen Intern Med. 2019;34(10):2210–2223.

[26] Britza SM, Byard RW, Musgrave IF. Traditional Chinese medicine-associated nephrotoxicity and the importance of herbal interactions–An overview. Pharmacol Res Mod Chin Med. 2022;3:100099.

[27] van Oosten MJ, Logtenberg SJ, Hemmelder MH, et al. Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls. Clin Kidney J. 2021;14(12):2497–2523.

[28] Khokhar A, Khan YH, Mallhi TH, et al. Effectiveness of pharmacist intervention model for chronic kidney disease patients; a prospective comparative study. Int J Clin Pharm. 2020;42(2):625–634.

[29] Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: indigestion and non-steroidal anti-inflammatory drugs. BMJ. 2001;323(7323):1236–1239.

[30] Cypes IN, Prohaska ES, Melton BL. Pharmacist impact on medication dosing and billable coding accuracy in outpatients with chronic kidney disease. J Am Pharm Assoc. 2021;61(2):e153–e158.

[31] Tesfaye WH, Erku D, Mekonnen A, et al. Medication non-adherence in chronic kidney disease: a mixed-methods review and synthesis using the theoretical domains framework and the behavioural change wheel. J Nephrol. 2021;34(4):1091–1125.

[32] Santoro A, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Degli Esposti L. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease. J Nephrol. 2022;35(2):463–472.

[33] Schutze A, Hohmann C, Haubitz M, Radziwill R, Benohr P. Medicines optimization for patients with chronic kidney disease in the outpatient setting: the role of the clinical pharmacist. Int J Pharm Pract. 2021;29(6):587–597.

[34] Lin MY, Chang MY, Wu PY, et al. Multidisciplinary care program in pre-end-stage kidney disease from 2010 to 2018 in Taiwan. J Formos Med Assoc. 2022;121 Suppl 1:S64–S72.

[35] Macedo E, Bihorac A, Siew ED, et al. Quality of care after AKI development in the hospital: consensus from the 22nd Acute Disease Quality Initiative (ADQI) conference. Eur J Intern Med. 2020;80:45–53.

Downloads

Published

2024-07-30

How to Cite

Naif Awad D Alrwaili, Budur Siyar Almutrafi, Mohammad Mansour N Alreshdi, Abdulrahman Jelwi S Alenazi, Jeza Saleh Alzabni, Aljubayri, Hezam Hathal H, … Mufreh Ames Mlahad Alrowily. (2024). Pharmacist-Led Medication Counseling and Its Effect on Treatment Adherence in Patients with Chronic Diseases. International Journal of Computational and Experimental Science and Engineering, 10(4). https://doi.org/10.22399/ijcesen.4673

Issue

Vol. 10 No. 4 (2024): IJCESEN

Section

Research Article

License

Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.